-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FiEIRnwQQXTX9W+DObFHk6GkV0W4ZtHPy5jG8CZHT7GdJkklOF/xJRfweN0VEr40 4oLt3IHvzJ2wR9XRKn3wSQ== 0000950135-97-003868.txt : 19970918 0000950135-97-003868.hdr.sgml : 19970918 ACCESSION NUMBER: 0000950135-97-003868 CONFORMED SUBMISSION TYPE: 10-Q/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 19970630 FILED AS OF DATE: 19970917 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: GENZYME CORP CENTRAL INDEX KEY: 0000732485 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 061047163 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q/A SEC ACT: SEC FILE NUMBER: 000-14680 FILM NUMBER: 97681445 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQ CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6172527500 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE CITY: CAMBRIDGE STATE: MA ZIP: 02139 10-Q/A 1 GENZYME CORPORATION 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 AMENDMENT NO. 1 ON FORM 10-Q/A --------- (X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 1997 ------------- OR ( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_______________to_______________ Commission file number 0-14680 ------- GENZYME CORPORATION - -------------------------------------------------------------------------------- (Exact name of registrant as specified in its charter) Massachusetts 06-1047163 - -------------------------------------------------------------------------------- (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) One Kendall Square, Cambridge, Massachusetts 02139 - -------------------------------------------------------------------------------- (Address of principal executive offices) (zip code) (617) 252-7500 - -------------------------------------------------------------------------------- (Registrant's telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No --- --- The number of shares outstanding of each of the issuer's series of common stock as of July 31, 1997:
Series Outstanding at July 31, 1997 ------ ---------------------------- Genzyme General Division Common Stock ("GGD Stock") 76,730,738 Genzyme Tissue Repair Division Common Stock ("GTR Stock") 15,715,885 Genzyme Molecular Oncology Division Common Stock ("GMO Stock") 3,928,571
2 GENZYME CORPORATION AND SUBSIDIARIES FORM 10-Q/A, JUNE 30, 1997 This Amendment No. 1 on Form 10-Q/A for the fiscal quarter ended June 30, 1997 has been filed to amend Part II, Item 4 "Submission of Matters to a Vote of Security Holders," in which the voting on the proposal described in subsection II a. thereof was previously erroneously reported as the voting on the proposal described in subsection II b. thereof, and vice versa. This Amendment No. 1 on Form 10-Q/A contains the corrected report on the voting on the proposals described under subsections II a. and II b. of Item 4. 2 3 GENZYME CORPORATION AND SUBSIDIARIES FORM 10-Q/A, JUNE 30, 1997 PART II. OTHER INFORMATION ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS I. The Company held an annual meeting of its stockholders on May 29, 1997. The following represents the results of the voting on proposals submitted to a vote of stockholders at such meeting: a. Proposal to elect two directors for a term of office expiring in 2000:
Nominee ------- Henri A. Termeer Number of Number of Number of Votes Number of Votes For Votes Withheld Abstaining Broker Non-Votes ---------- -------------- --------------- ---------------- GGD 58,318,091 520,720 0 0 GTR* 3,810,615 37,406 0 0 ---------- ------- -- -- Total 62,128,706 558,126 0 0
Nominee ------- Henry R. Lewis Number of Number of Number of Votes Number of Votes For Votes Withheld Abstaining Broker Non-Votes ---------- -------------- --------------- ---------------- GGD 58,318,872 519,939 0 0 GTR* 3,809,835 38,186 0 0 ---------- ------- -- -- Total 62,128,707 558,125 0 0
b. Proposal to amend the Company's 1990 Employee Stock Purchase Plan (the "ESPP") to increase the number of shares of GGD stock available shares for issuance under such plan from 1,500,000 to 2,000,000 shares.
Number of Number of Votes Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 46,595,790 11,943,850 299,171 0 GTR* 3,229,593 601,333 17,095 0 ---------- ---------- ------- -- Total 49,825,383 12,545,183 316,266 0
c. Proposal to amend the ESPP to increase the number of shares of GTR stock available for issuance under such plan from 600,000 to 1,100,000 shares.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 46,263,732 12,271,324 303,755 0 GTR* 3,100,525 729,356 18,140 0 ---------- ---------- ------- -- Total 49,364,257 13,000,680 321,895 0
d. Proposal to amend the Company's 1988 Director Stock Option Plan (the "Director Plan") to increase the number of shares of GGD stock available for issuance under such plan from 200,000 to 233,600 shares.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 51,891,846 6,658,603 288,362 0 GTR* 3,246,176 580,342 21,503 0 ---------- --------- ------- -- Total 55,138,022 7,238,945 309,865 0
3 4 GENZYME CORPORATION AND SUBSIDIARIES FORM 10-Q/A, JUNE 30, 1997 ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS (CONTINUED) e. Proposal to amend the Director Plan to increase the number of shares of GTR Stock available for issuance under such plan from 70,000 to 100,000 shares.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 51,894,710 6,653,286 290,815 0 GTR* 3,220,607 605,908 21,506 0 ---------- --------- ------- -- Total 55,115,317 7,259,194 312,321 0
---------- * Represents the actual number of shares of GTR Stock voted multiplied by .33. II. The Company held a special meeting of its stockholders on June 12, 1997. The following represents the results of the voting on proposals submitted to a vote of stockholders at such meeting: a. Proposal to approve the Merger Agreement between Genzyme and PharmaGenics which provides for the merger of PharmaGenics with and into Genzyme and the issuance of shares of GMO Stock in connection therewith.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 39,859,153 881,042 220,400 GTR* 2,264,547 59,707 28,361 ---------- ------- ------- Total 42,123,700 940,749 248,761 6,953,718
b. Proposal to amend and restate the articles of organization of Genzyme to redesignate Genzyme's existing classes of common stock as separate series of a single class of common stock and to authorize 150,000,000 shares of undesignated common stock that may be issued from time to time by the Genzyme Board in one or more series.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 45,764,726 1,756,657 249,597 0 GTR* 2,347,090 114,015 34,843 0 ---------- --------- ------- -- Total 48,111,816 1,870,672 284,440 0
c. Proposal to amend the 1990 Equity Incentive Plan to authorize the granting of awards under such plan relating to GMO stock.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 27,675,435 14,936,206 1,750,379 GTR* 1,662,846 794,153 38,948 ---------- ---------- --------- Total 29,338,281 15,730,359 1,789,327 3,408,961
d. Proposal to amend the Director Plan to authorize the granting of options to purchase GMO stock under such plan.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 30,770,739 13,280,794 310,487 GTR* 1,778,214 677,711 40,022 ---------- ---------- ------- Total 32,548,953 13,958,505 350,509 3,408,961
4 5 GENZYME CORPORATION AND SUBSIDIARIES FORM 10-Q/A, JUNE 30, 1997 ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS (CONTINUED) e. Proposal to amend the ESPP to authorize the granting of stock purchase rights under such plan relating to GMO stock.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 32,529,086 11,555,952 276,982 GTR* 1,912,640 544,172 39,135 ---------- ---------- ------- Total 34,441,726 12,100,124 316,117 3,408,961
f. Proposal to amend the Directors' Deferred Compensation Plan to authorize the distribution of shares of GMO stock credited to stock accounts under such plan.
Number of Number of Number of Votes Number of Votes for Votes Against Abstaining Broker Non-Votes ---------- ------------- --------------- ---------------- GGD 42,095,920 1,941,213 320,887 GTR* 2,327,073 127,984 40,890 ---------- --------- ------- Total 44,422,993 2,069,197 361,777 3,412,961
---------- * Represents the actual number of shares of GTR Stock voted multiplied by .33. 5 6 GENZYME CORPORATION AND SUBSIDIARIES FORM 10-Q/A, JUNE 30, 1997 SIGNATURES ---------- Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. GENZYME CORPORATION DATE: September 17, 1997 By: /s/ David J. McLachlan ---------------------------------------- David J. McLachlan Duly Authorized Officer and Executive Vice President, Finance; Chief Financial Officer 6 -----END PRIVACY-ENHANCED MESSAGE-----